CEBPA and acute myeloid leukemia: Our results indicate that the SNV rs2853669 has potential as a prognostic marker of survival in AML, in addition to the clinically used biomarkers FLT3-ITD, NPM1 and CEBPA mutations, which may further aid in treatment decisions such as allocation of patients to early stem cell transplantation.